Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | CD19-PD-1/CD28-CAR T cells |
Indication/Tumor Type | diffuse large B-cell lymphoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | diffuse large B-cell lymphoma | predicted - sensitive | CD19-PD-1/CD28-CAR T cells | Case Reports/Case Series | Actionable | In a Phase Ib trial, CD19-PD-1/CD28-CAR T cell treatment in two patients with CD274 positive diffuse large B-cell lymphoma resulted in complete remission (CR) after 3 months, however, disease progression was observed in one patient after 2 months, while the other patient achieved persistent CR. (PMID: 33028589). | 33028589 |
PubMed Id | Reference Title | Details |
---|---|---|
(33028589) | CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma. | Full reference... |